Flash Finance

Bilcare Ltd526853Corporate

Healthcare Research, Analytics & Technology Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹99.00
MCap ₹215 Cr · P/E 9.8
Bilcare Ltd — Stock analysis & AI research Bilcare Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹226 Cr
Sales · Jun 2026
+21.2% YoY
₹37 Cr
Operating Profit · Jun 2026
+234.4% YoY
16.4%
OPM % · Jun 2026
+178.0% YoY
₹15 Cr
Net Profit · Jun 2026
+253.4% YoY
₹5.39
EPS · Jun 2026
+434.8% YoY

📝 Bilcare Ltd — results explained

Quarter ended June 2026 (Q1 FY27)

Bilcare Ltd reported revenue of ₹226 crore for the quarter ended June 2026 (Q1 FY27), up 21.2% from ₹186 crore in the same quarter last year, and up 20.4% sequentially over the March 2026 quarter.

The company swung to a net profit of ₹15 crore from a net loss of ₹10 crore a year earlier. Earnings per share (EPS) came in at ₹5.39.

Operating profit stood at ₹37 crore — an operating margin (OPM) of 16.4%, compared with 5.9% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Bilcare Ltd posted revenue of ₹734 crore, a decline of 6.9% over FY25, with a net loss of ₹31 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹773 crore with a net loss of ₹6 crore.

Valuation snapshot

At the current price of ₹99.00, 526853 has a market capitalisation of ₹215 crore.

Within the Healthcare Research, Analytics & Technology industry, it is the 5th-largest of the 10 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 30.01%, foreign institutional investors (FIIs) 0.04%, public shareholders 69.95% of Bilcare Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹215 Cr
Current Price ?
₹99.0
P/E ?
N/A
Industry P/E ?
35.60
P/B ?
1.09
P/S ?
0.28
P/FCF ?
1.79
Enterprise Value ?
₹835 Cr
EV/EBITDA ?
11.86
PEG ?
N/A
Earnings Yield ?
5.3%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹773 Cr
OPM ?
9.1%
Profit after tax (TTM) ?
₹-6 Cr
EPS (TTM) ?
₹-2.95
ROCE ?
6.0%
ROE ?
-3.2%
ROA ?
-0.8%
Growth
Sales — latest qtr ?
₹226 Cr
PAT — latest qtr ?
₹15 Cr
YoY qtr sales growth ?
21.2%
YoY qtr profit growth ?
253.4%
Sales growth (3y) ?
-9%
Sales growth (5y) ?
3%
Profit growth (3y) ?
37%
Profit growth (5y) ?
16%
Financial Health
Debt ?
₹620 Cr
Debt to Equity ?
3.15
Interest Coverage ?
0.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
30.01%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
76.2%
Return 6 months ?
72.7%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 234182190175200194202198194186178181188226 +21.2% +20.4%
Operating Profit 14131717-8198118113131737 +234.4% +118.7%
Other Income 23131494-6-621643122 -71.2% -86.0%
Interest 1119202123212419191919171818 -2.5% +2.2%
Depreciation 91010111312111251212554 -64.4% -14.0%
Profit Before Tax 225-13-13-10-35-10-33-276-13-24-6715 +214.5% +114.5%
Net Profit 78-13-12-14-20-15-30-1612-10-23-6815 +253.4% +90.7%
EPS 19.63-3.36-3.22-2.91-4.63-2.71-6.81-3.047.47-1.61-5.250.415.685.39 +434.8% -5.1%
OPM % 6.2% 7.4% 8.8% 9.9% -4.1% 9.8% 3.8% 5.4% 4.0% 5.9% 1.9% 7.2% 9.0% 16.4% +178.0% +82.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹788 Cr ₹734 Cr ₹773 Cr -6.9%
Operating Profit ₹45 Cr ₹44 Cr ₹70 Cr -1.1%
OPM % 5.70% 6.06% 9.10% +6.3%
NPM % -6.23% -4.24% -0.83% +31.9%
Other Income ₹12 Cr ₹26 Cr ₹22 Cr +111.1%
Depreciation ₹39 Cr ₹34 Cr ₹26 Cr -13.8%
Interest ₹83 Cr ₹72 Cr ₹72 Cr -12.5%
EBIT ₹6 Cr ₹11 Cr ₹44 Cr +81.7%
PBT ₹-64 Cr ₹-35 Cr ₹-7 Cr +45.1%
Tax — — ₹-0 Cr —
Net Profit ₹-49 Cr ₹-31 Cr ₹-6 Cr +36.7%
EPS ₹-5.09 ₹-0.77 ₹6.23 +84.9%
Material Cost — — ₹143 Cr —
Employee Cost — — ₹20 Cr —
Extraordinary Items — — ₹-2 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 24242424 +0.0%
Reserves 507474445173 -61.1%
Borrowings 639756682620 -9.1%
Other Liabilities 42431426626 -90.2%
Total Liabilities 1,5931,5681,417843 -40.5%
Fixed Assets 1,0451,038949433 -54.4%
CWIP 1148 +100.0%
Investments 281114 +27.3%
Other Assets 545521453387 -14.6%
Total Assets 1,5931,5681,417843 -40.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -76285128 +50.6%
Cash from Investing Activity 36-10681-6 -107.4%
Cash from Financing Activity -1936-169-132 +21.9%
Net Cash Flow 10-7-3-10 -233.3%
Free Cash Flow 11-34140120 -14.3%
CFO/OP -6%162%193%284% +47.2%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 70735554 -1.8%
Inventory Days 42778086 +7.5%
Days Payable 77705770 +22.8%
Cash Conversion Cycle 34807869 -11.5%
Working Capital Days -1012-528 +660.0%
ROCE % 3%1%1%6% +500.0%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 30.01%30.01%30.01%30.01% +0.0%
FIIs 0.04%0.04%0.04%0.04% +0.0%
Public 69.95%69.94%69.95%69.95% +0.0%
No. of Shareholders 17,04716,51316,06815,824 -1.5%

⚖️ Peer comparison

Industry: Healthcare Research, Analytics & Technology · 10 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 INDGN Indegene ₹597.05 14,377 35.8 3,812 401 16.7% 10.5% 23.6% -1.5% 39.7% -0.2%
2 SUVEN Suven Life ₹286.25 8,088 — 9 -353 -3955.0% -3815.2% 6.9% -71.9% 114.3% -148.5%
3 VIMTALABS Vimta Labs ₹637.20 2,847 35.7 419 80 34.4% 19.1% 18.0% 19.5% 11.3% 10.7%
4 FABTECH Fabtech Technologies ₹145.66 647 44.8 364 14 2.4% 4.0% — — 10.3% 168.7%
5 526853 Bilcare Ltd-$ ₹61.25 215 — 773 -6 9.1% -0.8% -6.9% 36.7% 21.2% 253.4%
6 TAKE Take Solutions ₹12.69 186 14.6 85 13 -2.0% 15.2% — -71.0% — 216.8%
7 536565 Novelix Pharmaceuticals ₹19.88 181 13.2 147 4 3.1% 2.5% 330.7% 2218.2% 65.2% 971.7%
8 538837 Jeevan Scientific ₹50.96 178 22.6 71 5 20.5% 7.2% 31.4% 1371.4% 107.7% 127.0%
9 543309 Adeshwar Meditex ₹27.50 24 31.2 56 1 4.9% 2.2% — — -30.4% -60.4%
10 540729 Vanta Bioscience ₹51.45 15 333.1 2 0 55.8% 6.1% — — 357.6% 240.9%
❓ Frequently asked questions
What was Bilcare Ltd's revenue in Q1 FY27?
Bilcare Ltd reported revenue of ₹226 crore for the quarter ended June 2026 (Q1 FY27), up 21.2% from ₹186 crore in the same quarter last year, and up 20.4% sequentially over the March 2026 quarter.
What was Bilcare Ltd's net profit in Q1 FY27?
The company swung to a net profit of ₹15 crore from a net loss of ₹10 crore a year earlier. Earnings per share (EPS) came in at ₹5.39.
What is 526853's market capitalisation and P/E ratio?
At the current price of ₹99.00, 526853 has a market capitalisation of ₹215 crore.
Who owns Bilcare Ltd? (shareholding pattern)
As of Mar 2026, promoters held 30.01%, foreign institutional investors (FIIs) 0.04%, public shareholders 69.95% of Bilcare Ltd.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI